Suppr超能文献

哮喘中的慢性应激与糖皮质激素受体抵抗。

Chronic Stress and Glucocorticoid Receptor Resistance in Asthma.

机构信息

Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires (UNNOBA-UNSADA-CONICET), Junín, Argentina.

Instituto de Investigaciones Biomédicas (UCA-CONICET), Buenos Aires, Argentina.

出版信息

Clin Ther. 2020 Jun;42(6):993-1006. doi: 10.1016/j.clinthera.2020.03.002. Epub 2020 Mar 26.

Abstract

PURPOSE

Chronic and persistent exposure to negative stress can lead to adverse consequences on health. Particularly, psychosocial factors were found to increase the risk and outcome of respiratory diseases like asthma. Glucocorticoids (GCs) are the most efficient anti-inflammatory therapy for asthma. However, a significant proportion of patients don't respond adequately to GC administration. GC sensitivity is modulated by genetic and acquired disease-related factors. Additionally, it was proposed that endogenous corticosteroids may limit certain actions of synthetic GCs, contributing to insensitivity. Psychological and physiological stresses activate the hypothalamic-pituitary-adrenal axis, increasing cortisol levels. Here, we review the mechanism involved in altered GC sensitivity in asthmatic patients under stressful situations. Strategies for modulation GC sensitivity and improving GC therapy are discussed.

METHODS

PubMed was searched for publications on psychological chronic stress and asthma, GC resistance in asthma, biological mechanisms for GC resistance, and drugs for steroid-resistant asthma, including highly potent GCs.

FINDINGS

GC resistance in patients with severe disease remains a major clinical problem. In asthma, experimental and clinical evidence suggests that chronic stress induces inflammatory changes, contributing to a worse GC response. GC resistant patients can be treated with other broad-spectrum anti-inflammatory drugs, but these generally have major side effects. Different mechanisms of GC resistance have been described and might be useful for developing new therapeutic strategies against it. Novel drugs, such as highly potent GCs, phosphoinositide 3-kinase-delta inhibitors that reestablish histone deacetylase-2 function, decrease of GC receptor phosphorylation by p38 mitogen-activated protein kinase inhibitors, or phosphatase activators, are currently in clinical development and might be combined with GC therapy in the future. Furthermore, microRNAs (small noncoding RNA molecules) operate as posttranscriptional regulators, providing another level of control of GC receptor levels. Empirical results allow postulating that the detection and study of microRNAs might be a promising approach to better characterize and treat asthmatic patients.

IMPLICATIONS

Many molecular and cellular pathobiological mechanisms are responsible of GC resistance. Therefore detecting specific biomarkers to help identify patients who would benefit from new therapies is crucial. Stress consitutes a negative aspect of current lifestyles that increase asthma morbidity and mortality. Adequate stress management could be an important and positive intervention.

摘要

目的

长期持续接触负面压力会对健康产生不良后果。特别是,心理社会因素被发现会增加哮喘等呼吸道疾病的风险和预后。糖皮质激素(GCs)是治疗哮喘最有效的抗炎药物。然而,相当一部分患者对 GC 治疗反应不足。GC 敏感性受遗传和获得性疾病相关因素的调节。此外,有人提出内源性皮质类固醇可能会限制合成 GCs 的某些作用,导致不敏感。心理和生理应激会激活下丘脑-垂体-肾上腺轴,增加皮质醇水平。在这里,我们综述了应激状态下哮喘患者 GC 敏感性改变的相关机制。讨论了调节 GC 敏感性和改善 GC 治疗的策略。

方法

在 PubMed 上搜索关于心理慢性应激和哮喘、哮喘 GC 抵抗、GC 抵抗的生物学机制以及包括高效能 GCs 在内的治疗类固醇抵抗性哮喘的药物的文献。

发现

严重疾病患者的 GC 抵抗仍然是一个主要的临床问题。在哮喘中,实验和临床证据表明,慢性应激会引起炎症变化,导致 GC 反应更差。GC 抵抗患者可以用其他广谱抗炎药物治疗,但这些药物通常有很大的副作用。已经描述了不同的 GC 抵抗机制,这可能有助于开发针对它的新治疗策略。新型药物,如高效能 GCs、恢复组蛋白去乙酰化酶-2 功能的磷酸肌醇 3-激酶-δ 抑制剂、通过 p38 丝裂原活化蛋白激酶抑制剂减少 GC 受体磷酸化、或磷酸酶激活剂,目前正在临床开发中,未来可能与 GC 治疗联合使用。此外,微小 RNA(小非编码 RNA 分子)作为转录后调节剂起作用,为 GC 受体水平提供了另一个控制水平。经验结果允许假设,检测和研究微小 RNA 可能是一种有前途的方法,可以更好地对哮喘患者进行特征描述和治疗。

意义

许多分子和细胞病理生物学机制是 GC 抵抗的原因。因此,检测有助于确定哪些患者将受益于新疗法的特定生物标志物至关重要。压力是增加哮喘发病率和死亡率的现代生活的负面影响。适当的压力管理可能是一种重要的积极干预措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验